Agios piv­ots away from on­col­o­gy, auc­tion­ing off can­cer pipeline for $2B and shift­ing the spot­light in re­struc­tur­ing

Agios made its name as a can­cer drug de­vel­op­er un­der the leg­endary founder David Schenkein, who took the com­pa­ny from a fa­mous­ly blank sheet of pa­per to com­mer­cial­iza­tion be­fore he stepped aside a cou­ple of years ago and hand­ed the reins to Cel­gene vet Jack­ie Fouse. But now Fouse, who’s had to con­tend with some set­backs along the way, has a whole new fu­ture in mind.

And it doesn’t have any­thing to do with can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER